Dorien H. Nieman mainly focuses on Psychiatry, Psychosis, Schizophrenia, Risk factor and Cognition. Her research in Psychiatry intersects with topics in Internal medicine, Proportional hazards model, Clinical psychology and Hazard ratio. Dorien H. Nieman works mostly in the field of Psychosis, limiting it down to concerns involving Developmental psychology and, occasionally, Audiology.
Her work carried out in the field of Schizophrenia brings together such families of science as First episode, Mental health and Prospective cohort study. Her Risk factor research incorporates elements of Intervention, Relative risk, Psychological intervention and Antipsychotic. Her work carried out in the field of Cognition brings together such families of science as Anhedonia, Intention-to-treat analysis, Psychopathology, Confidence interval and Number needed to treat.
Her primary scientific interests are in Psychosis, Psychiatry, Clinical psychology, Schizophrenia and Ultra high risk. Her Psychosis study incorporates themes from Audiology, Young adult, Psychopathology, First episode and Risk factor. As a part of the same scientific family, Dorien H. Nieman mostly works in the field of Young adult, focusing on Proportional hazards model and, on occasion, Prospective cohort study.
Her At risk mental state, Cognitive behavioral therapy, Neuropsychology, Cognition and Cannabis study are her primary interests in Psychiatry. Her Clinical psychology research incorporates themes from Psychological intervention, Intervention, Anxiety, Mental health and Depression. Her studies in Schizophrenia integrate themes in fields like Meta-analysis, Neurocognitive and Cohort.
Dorien H. Nieman focuses on Psychosis, Clinical psychology, Schizophrenia, Psychiatry and Psychopathology. The Ultra high risk research Dorien H. Nieman does as part of her general Psychosis study is frequently linked to other disciplines of science, such as Immigration, therefore creating a link between diverse domains of science. Her Clinical psychology study combines topics in areas such as Psychological intervention, Mental health and Psychological resilience.
Her Schizophrenia research includes elements of Major depressive disorder, Neurocognitive, Cognition and Hazard ratio. Her study on Antidepressant and Early intervention in psychosis is often connected to Risk assessment and Suicidal ideation as part of broader study in Psychiatry. Her Psychopathology research is multidisciplinary, incorporating perspectives in Clinical trial and Montgomery–Åsberg Depression Rating Scale.
Her scientific interests lie mostly in Psychological intervention, Clinical psychology, Schizophrenia, Eicosapentaenoic acid and Docosahexaenoic acid. Her Psychological intervention study results in a more complete grasp of Psychiatry. Her research on Clinical psychology focuses in particular on Psychopathology.
Her research links Psychosis with Schizophrenia. Her study in the field of Prodrome also crosses realms of Schizophreniform disorder. Her work in Randomized controlled trial tackles topics such as Confidence interval which are related to areas like At risk mental state, Intensive care medicine, Meta-analysis and Stage.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification
Paolo Fusar-Poli;Paolo Fusar-Poli;Marco Cappucciati;Marco Cappucciati;Stefan Borgwardt;Scott W. Woods.
JAMA Psychiatry (2016)
The Validity of the 16-Item Version of the Prodromal Questionnaire (PQ-16) to Screen for Ultra High Risk of Developing Psychosis in the General Help-Seeking Population
Helga K. Ising;Wim Veling;Rachel L. Loewy;Marleen W. Rietveld.
Schizophrenia Bulletin (2012)
Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
Eva Velthorst;Dorien H. Nieman;Hiske E. Becker;Reinaud van de Fliert.
Schizophrenia Research (2009)
Cognitive Behavioral Therapy for Subjects at Ultrahigh Risk for Developing Psychosis: A Randomized Controlled Clinical Trial
Mark van der Gaag;Dorien H. Nieman;Judith Rietdijk;Sara Dragt.
Schizophrenia Bulletin (2012)
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
Patrick D. McGorry;Barnaby Nelson;Connie Markulev;Hok Pan Yuen.
JAMA Psychiatry (2017)
Ultra high-risk state for psychosis and non-transition: a systematic review.
Andor E. Simon;Eva Velthorst;Dorien H. Nieman;Don Linszen.
Schizophrenia Research (2011)
Disability in people clinically at high risk of psychosis
Eva Velthorst;Dorien H. Nieman;Don Linszen;Hiske Becker.
British Journal of Psychiatry (2010)
White-matter markers for psychosis in a prospective ultra-high-risk cohort.
O. J. N. Bloemen;M. B. de Koning;N. Schmitz;D. H. Nieman.
Psychological Medicine (2010)
Early intervention in patients at ultra high risk of psychosis: benefits and risks.
M. B. de Koning;O. J. N. Bloemen;T. A. M. J. van Amelsvoort;H. E. Becker.
Acta Psychiatrica Scandinavica (2009)
Adapted cognitive–behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression
E. Velthorst;M. Koeter;M. van der Gaag;D. H. Nieman.
Psychological Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: